Merck & Co./$MRK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Merck & Co.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
Ticker
$MRK
Sector
Primary listing
NYSE
Employees
74,000
Headquarters
Website
Merck & Co. Metrics
BasicAdvanced
$209B
11.10
$7.56
0.32
$3.24
3.86%
Price and volume
Market cap
$209B
Beta
0.32
52-week high
$102.97
52-week low
$73.31
Average daily volume
12M
Dividend rate
$3.24
Financial strength
Total debt to equity
72.161
Interest coverage (TTM)
21.38%
Profitability
EBITDA (TTM)
31,542
Gross margin (TTM)
78.02%
Net profit margin (TTM)
29.63%
Operating margin (TTM)
42.40%
Effective tax rate (TTM)
12.71%
Revenue per employee (TTM)
$870,000
Management effectiveness
Valuation
Price to earnings (TTM)
11.099
Price to revenue (TTM)
3.277
Price to book
4.28
Price to tangible book (TTM)
17.19
Dividend yield (TTM)
3.86%
Forward dividend yield
3.86%
Growth
Revenue change (TTM)
1.68%
Earnings per share change (TTM)
58.06%
3-year revenue growth (CAGR)
2.89%
10-year revenue growth (CAGR)
4.91%
3-year earnings per share growth (CAGR)
7.95%
10-year earnings per share growth (CAGR)
7.20%
3-year dividend per share growth (CAGR)
5.57%
10-year dividend per share growth (CAGR)
5.98%
What the Analysts think about Merck & Co.
Analyst ratings (Buy, Hold, Sell) for Merck & Co. stock.
Bulls say / Bears say
Merck’s flagship immuno-oncology therapy Keytruda delivered $8.1 billion in Q3 2025 sales, up 10% year-over-year, driven by strong uptake across both early-stage and metastatic cancer indications (Reuters).
Merck agreed to acquire UK-based Verona Pharma for about $10 billion, gaining Ohtuvayre—a first-in-class COPD treatment projected to reach peak annual sales of $3 billion–$4 billion by the mid-2030s, diversifying its portfolio ahead of Keytruda patent cliffs (Reuters).
Merck Animal Health announced an $895 million expansion of its De Soto, Kansas manufacturing facility to boost vaccine and biologics capacity, supporting double-digit segment growth and reinforcing its long-term production capabilities (Reuters).
Merck’s Gardasil vaccine sales plunged 55% year-over-year to $1.1 billion in Q2 2025 as weak demand in China and a pause on shipments drove a sharp decline in its HPV franchise (Reuters).
Merck narrowed its full-year 2025 revenue outlook to $64.5 billion–$65.0 billion following Q3 2025 results, sending shares down 3% and signaling near-term growth headwinds (Reuters).
Investors remain concerned about Merck’s heavy reliance on Keytruda—now over 47% of sales—as the drug faces looming patent expirations in 2028, potential pricing reforms and upcoming biosimilar competition (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Merck & Co. Financial Performance
Revenues and expenses
Merck & Co. Earnings Performance
Company profitability
Merck & Co. News
AllArticlesVideos
Merck and Blackstone enter research agreement to develop cancer therapy for $700 million
Reuters1 day ago
Merck Signs Agreement with Dr. Falk Pharma GmbH for Certain Development and Commercialization Rights to MK-8690 (PRA-052) an Investigational Anti-CD30 Ligand Monoclonal Antibody
Business Wire1 day ago
Merck Enters into Research and Development Funding Agreement with Blackstone Life Sciences for Sacituzumab Tirumotecan (sac-TMT)
Business Wire1 day ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Merck & Co. stock?
Merck & Co. (MRK) has a market cap of $209B as of November 05, 2025.
What is the P/E ratio for Merck & Co. stock?
The price to earnings (P/E) ratio for Merck & Co. (MRK) stock is 11.1 as of November 05, 2025.
Does Merck & Co. stock pay dividends?
Yes, the Merck & Co. (MRK) stock pays dividends to shareholders. As of November 05, 2025, the dividend rate is $3.24 and the yield is 3.86%. Merck & Co. has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Merck & Co. dividend payment date?
The next Merck & Co. (MRK) dividend payment date is unconfirmed.
What is the beta indicator for Merck & Co.?
Merck & Co. (MRK) has a beta rating of 0.32. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.